makinezmoney
2 년 전
$QLIS: Excellent NEWS... another Business coming in !
https://www.globenewswire.com/news-release/2022/11/17/2558423/0/en/Qualis-Innovations-Inc-recently-announces-its-financial-results-along-with-updated-form-Company-s-Chief-Executive.html
GO $QLIS
**********************************************************************************
Qualis Innovations Inc. recently announces its financial results along with updated form Company’s Chief Executive
November 17, 2022 10:22 ET | Source: Qualis Innovations, Inc.
...
Chadds Ford, Pennsylvania, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol “QLIS”, recently announced its financial 10-Q report on November 14, 2022. The Company continues to progress on competition in its development on the SOLACE device. The company’s 10Q reports currently shows the Company has total assets of approximately 453K and total debt of less than 84K please see 10Q report for further details. Dr. Joseph Pergolizzi provided the following update to the Company’s progress and direction
As acting Chief Executive Officer of Qualis Innovations, I want to thank you for your support for Qualis Innovations and for your loyalty and patience while we work to build value in your company. I am writing you to provide an update on the progress management has made in positioning your company to become a known and respected leader in non-drug pain management and in providing innovative, effective, and cost-saving solutions for today’s challenging opioid crisis.
It is well known that death rates and costly hospitalizations from opioids are soaring out of control. CDC’s National Center for Health Statistics reports there were an estimated 107,622 opioid related drug overdose deaths in the United States during 2021, an increase of nearly 15% from the 93,655 deaths estimated in 2020. It is also estimated that opioid overdoses are costing hospitals $11 billion per year. The problem is so widespread that the Gallup Poll found 78% of those polled prefer pain management solutions that are drug free.
Clearly, the need for non-opioid pain medical device orientated solutions has never been greater. Now I will explain why Qualis’ management and myself are so excited to write to you about our plans and progress concerning this very big problem and why I believe we are so uniquely positioned to bring desperately needed solutions that we are confident have the potential to help alleviate the problem and at the same time, create substantial added value for your company.
On the drug-free pain management front, Qualis is moving to commercialize the SOLACE™ device that utilizes a directional handpiece to apply the planar heat more precisely to discrete areas of the body. Our Solace™ device is intended to provide clinicians with greater therapeutic control. As experts in pain management, we believe the market will be receptive to our new drug free pain treatment device and expect to be submitting our 510(k) to the FDA for the Solace device in the next quarter.
Nova One Advisor reports the market for non-opioid pain treatment is expected to grow from $38.9 billion in 2021 to $78 billion by 2030. Qualis is also in discussions to acquire or license other approved non-drug electroceutical pain management devices.
On another very exciting front, Qualis is in active discussions to acquire a company focused on opioid addiction and recovery solutions. Qualis believes this acquisition can become a formidable profit center because of the potential to help patients and save hospitals and payers billions of dollars from avoidable episodes of care. These are all important developments that we expect can lead to substantial future growth.
While there can never be guarantees of success, management is nonetheless confident and highly motivated. It is management skills that will help drive our efforts to successful conclusions. A little about myself. I am a well-known, leading pain management specialist and an internationally recognized thought leader in anesthesiology, internal medicine, perioperative care, pain medicine, critical and palliative care, pharmacology, drug development, and regulatory affairs.
Additionally, I am a Co-Founder of Enalare Therapeutics that recently announced a $50.3 million award for from the Biomedical Advanced Research and Development Authority.
I am a drug and device regulatory subject matter expert and a top consultant for numerous Blockbuster-branded medications. I am an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Qualis.
I am the co-founder of NEMA Research, Inc., a specialty CRO, a former invited subcommittee member of the FDA Safe Use Initiative, an SGE V.A. Health Grant Reviewer, a section Chairman of PAINWEEK, and Consultant to Global Pain Initiative’s Board of Directors.
I am the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit and a former part-time adjunct assistant professor in the Department of Medicine at Johns Hopkins University School of Medicine. I have published over 300 peer-reviewed medical articles, abstracts and posters and am frequently invited to share my presentations at scientific conferences and television around the world.
I am the recipient of numerous awards including Top Critical Care Medicine Doctor and Best in Medicine. I was a General Partner in the Life Science Equity Partners and have extensive executive board experience. Qualis’ management and myself thank you for your continued support and we look forward to announcing further developments as they unfold. Yours truly, Dr. Joseph Pergolizzi, CEO
About Qualis Innovations Inc
Through our wholly owned subsidiary mPathix Health Inc. we are a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.
We are developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen. We are currently developing our SOLACE device which is a non-invasive medical device that uses electromagnetic induction to generate deep heat below the surface of the skin to reduce and relieve pain. SOLACE™ delivers radio frequency (RF) energy continuously and thereby delivers thermal effects to the tissue and utilizes several differentiated features vs other radio frequency devices currently on the market. We believe that our SOLACE device product will provide clinicians and patients with new and differentiated set of pain management tools to meet the diversity of patient needs. We plan to submit our 510(k) application with the Federal Drug Administration (“FDA’) by the fourth quarter of 2022.
A key element to the Company’s growth strategy is to acquire the rights to or develop existing devices. Large device companies have increased the minimum market opportunity they require in order to commit marketing resources to their products. As a result, there are many products that are unsupported by such companies and are currently scheduled to be phased out or “sunsetted.” Qualis Innovations believes that it can create significant value by developing or acquiring rights to a portfolio of such products, expanding their therapeutic uses and/or markets, improving or enhancing such products and dedicating the appropriate amount of marketing and other resources to maximize the value of the Company’s portfolio.
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Please visit our SEC filings or Company's website for more information on the full results and management's plan.
Contact:
John Ballard 303-885-5501
website: qualisinnovations.com
oldstocks
2 년 전
$FDCT The Offering: Qualis Innovations through CIM Securities, LLC
CIM Securities, LLC is now 80% owned by FDCTech $FDCT a 2-3 cent stock.
FDCTech has been expanding into financial markets.
Qualis Innovations, Inc., is offering on a “best efforts” basis through CIM Securities, LLC, a FINRA member broker-dealer as the managing placement agent and the officers and directors of the Company solely to verified accredited investors under Section 4(a)(2) and Rule 506(c) of Regulation D promulgated under the Securities Act of 1933, as amended up to 4,000,000 shares of 8% PIK Dividend Series A Convertible Participating Preferred Stock, par value $0.001 per share for a purchase price of $1.00 per Share. The Offering will terminate on the earliest of: (a) the date the Company, in its discretion, elects to terminate, (b) the date upon which all Shares have been sold, subject to an increase in the size of the Offering or (c) October 5, 2022, unless extended by the Company for up to an additional Ninety (90) days. An Investment into these Securities is highly risky, an investor must be willing to bear the entire loss of principal and be willing to hold these securities for an indefinite period of time.
About CIM Securities:
CIM Securities is an independent investment bank that serves micro-cap and small-cap companies by providing capital raising solutions and merger and acquisition services for companies seeking growth capital.
CIM Securities offers private placement transactions where shares of or other investments in a particular company are purchased directly from the issuers. CIM Securities also provide brokerage account services through its relationship with a clearing firm, Hilltop Securities.
makinezmoney
2 년 전
$QLIS: Excellent NEWS... $4Milly Funding, SOLACE Device
Now $1.90 and only 25k FLOAT.
LOWEST FLOAT EVER !!!!!!!!!!!!!!!!!!
GO $QLIS
***********************************************************************
Qualis Innovations Inc. enters into an Agreement with CIM Securities to raise up to $4,000,000 in Funding
August 24, 2022 09:00 ET | Source: Qualis Innovations, Inc.
...
Chadds Ford, Pennsylvania, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under the symbol “QLIS” entered into an agreement with CIM Securities to raise up to $4,000,000 through a Series A preferred stock offering open to accredited investors .
Through our wholly owned subsidiary mPathix Health Inc. we are a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.
We are developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen. We are currently developing our SOLACE device which is a non-invasive medical device that uses electromagnetic induction to generate deep heat below the surface of the skin to reduce and relieve pain. SOLACE™ delivers radio frequency (RF) energy continuously and thereby delivers thermal effects to the tissue and utilizes several differentiated features vs other radio frequency devices currently on the market. We believe that our SOLACE device product will provide clinicians and patients with new and differentiated set of pain management tools to meet the diversity of patient needs. We plan to submit our 510(k) application with the Federal Drug Administration (“FDA’) by the fourth quarter of 2022.
A key element to the Company’s growth strategy is to acquire the rights to or develop existing devices. Large device companies have increased the minimum market opportunity they require in order to commit marketing resources to their products. As a result, there are many products that are unsupported by such companies and are currently scheduled to be phased out or “sunsetted.” Qualis Innovations believes that it can create significant value by developing or acquiring rights to a portfolio of such products, expanding their therapeutic uses and/or markets, improving or enhancing such products and dedicating the appropriate amount of marketing and other resources to maximize the value of the Company’s portfolio.
The Offering:
Qualis Innovations, Inc., is offering on a “best efforts” basis through CIM Securities, LLC, a FINRA member broker-dealer as the managing placement agent and the officers and directors of the Company solely to verified accredited investors under Section 4(a)(2) and Rule 506(c) of Regulation D promulgated under the Securities Act of 1933, as amended up to 4,000,000 shares of 8% PIK Dividend Series A Convertible Participating Preferred Stock, par value $0.001 per share for a purchase price of $1.00 per Share. The Offering will terminate on the earliest of: (a) the date the Company, in its discretion, elects to terminate, (b) the date upon which all Shares have been sold, subject to an increase in the size of the Offering or (c) October 5, 2022, unless extended by the Company for up to an additional Ninety (90) days. An Investment into these Securities is highly risky, an investor must be willing to bear the entire loss of principal and be willing to hold these securities for an indefinite period of time.
About CIM Securities:
CIM Securities is an independent investment bank that serves micro-cap and small-cap companies by providing capital raising solutions and merger and acquisition services for companies seeking growth capital.
CIM Securities offers private placement transactions where shares of or other investments in a particular company are purchased directly from the issuers. CIM Securities also provide brokerage account services through its relationship with a clearing firm, Hilltop Securities.
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Please visit our SEC filings or Company's website for more information on the full results and management's plan.
Contact:
John Ballard 303-885-5501
website: qualisinnovations.com
makinezmoney
2 년 전
$QLIS: Big news coming in 3wks.... SOLACED DEVICE !!!!!!!!!!!!!
You heard it hear first.
Non-Invasive Pain Treatment from such a SUPER LOW FLOATER !!!!!!!!
GO $QLIS
*************************************************************************************
Qualis Innovations Inc. will Present at the 16th PAINWEEK Conference September 6-9 at The Cosmopolitan Of Las Vegas
August 22, 2022 09:53 ET | Source: Qualis Innovations, Inc.
...
Chadds Ford, Pennsylvania, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol “QLIS”, will be presenting at PAINWEEK 2022. The conference will be held from September 6-9 at The Cosmopolitan of Las Vegas. Our Chief Executive Officer, Dr. Joseph V. Pergolizzi, Jr will be presenting at the conference. The abstract will focus on non-invasive devices that may augment the treatment of musculoskeletal pain conditions.
Dr. Joseph V. Pergolizzi, Jr. has been our acting Chief Executive Officer since October 2021 Dr. Pergolizzi is an internationally recognized thought leader in anesthesiology, internal medicine, perioperative care, pain medicine, critical and palliative care, pharmacology, drug development, and regulatory affairs. As a drug and device regulatory subject matter expert. He is the co-founder of NEMA Research, Inc., where he has been employed as the Chief Operating Officer since June, 1997 and where he is currently employed. Dr. Pergolizzi is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit and a former part-time adjunct faculty member in the Department of Medicine at Johns Hopkins University School of Medicine. Dr. Pergolizzi has published over 300 peer-reviewed medical articles and is frequently invited to share his presentations at scientific conferences around the world. He is the recipient of numerous awards including Top Critical Care Medicine Doctor and Best in Medicine. Dr. Pergolizzi was a General Partner in the Life Science Equity Partners and has extensive executive board experience
Dr. Joseph V. Pergolizzi, Jr stated that he is “excited to present on these alternative treatment options due to the ever growing opioid epidemic, and the increased need and demand to treat chronic pain without the use of drugs and other potential harmful invasive treatments.”
About Qualis Innovations Inc
Through our wholly owned subsidiary mPathix Health Inc. we are a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.
We are developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen. We are currently developing our SOLACE device which is a non-invasive medical device that uses electromagnetic induction to generate deep heat below the surface of the skin to reduce and relieve pain. SOLACE™ delivers radio frequency (RF) energy continuously and thereby delivers thermal effects to the tissue and utilizes several differentiated features vs other radio frequency devices currently on the market. We believe that our SOLACE device product will provide clinicians and patients with new and differentiated set of pain management tools to meet the diversity of patient needs. We plan to submit our 510(k) application with the Federal Drug Administration (“FDA’) by the fourth quarter of 2022.
A key element to the Company’s growth strategy is to acquire the rights to or develop existing devices. Large device companies have increased the minimum market opportunity they require in order to commit marketing resources to their products. As a result, there are many products that are unsupported by such companies and are currently scheduled to be phased out or “sunsetted.” Qualis Innovations believes that it can create significant value by developing or acquiring rights to a portfolio of such products, expanding their therapeutic uses and/or markets, improving or enhancing such products and dedicating the appropriate amount of marketing and other resources to maximize the value of the Company’s portfolio.
About Painweek:
PAINWeek 2022 National Conference is going into its 16th year, it remains the largest and preferred destination for frontline practitioners in pain management. The conference will be convened September 6-9 at The Cosmopolitan of Las Vegas. Over 90 hours of multidisciplinary continuing medical education will be presented across the 4-day conference. This year’s Keynote will be “Meet Me at the Corner of Opportunity and Adversity: A Tribute to Jeffrey Fudin.”
For further information, please visit https://www.painweek.org/
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Please visit our SEC filings or Company's website for more information on the full results and management's plan.
Contact:
John Ballard 303-885-5501
website: qualisinnovations.com
makinezmoney
3 년 전
$QLIS: IPO Regiistration AMended
https://docoh.com/filing/1871181/0001493152-22-010489/QLIS-S1A
Presently, the Company is in the process of preparing the documents necessary to submit an application to the FDA for clearance of our planned device. We plan on also filing a provisional patent for the changes and new development of our device over our previous licensed device from LCMD, The Company has an accumulated deficit of $2,704,772. It is anticipated that the total expected financial outlay to complete the development and FDA application is approximately $250,000, combined with operating expenses the Company may not be able to have enough cash flow to support the Company’s daily operations resulting in an opinion by the auditors of the Company continuing as a going concern.
We anticipate that our SOLACE device will be cleared by the FDA via the 510k process and that it will be deemed to be substantially equivalent to the identified predicate device called the Bebe device, The Bebe device was originally cleared by the FDA in 2014 by the Marchito Entities and subsequently sold to LCMD via an Asset Purchase Agreement and an Intellectual Property License Agreement. The Bebe device is indicated for use in the treatment of selected medical conditions such as pain relief, muscle spasms, and joint contractures, but not for the treatment of malignancies.
GO $QLIS
makinezmoney
3 년 전
$QLIS: Biggggggggg news......... Dr. Robert Bilkovski
Qualis Innovations Inc. Announces the Appointment of Dr. Robert Bilkovski as Chief Scientific Officer of mPathix Health Inc.
1:46 PM ET 7/14/21 | GlobeNewswire
Qualis Innovations Inc. Announces the Appointment of Dr. Robert Bilkovski as Chief Scientific Officer of mPathix Health Inc.
Chadds Ford, PA, July 14, 2021 (GLOBE NEWSWIRE) -- mPathix Health Inc., a wholly owned subsidiary of Qualis Innovations Inc., (OTC: QLIS), a pain solutions company focused on developing and commercializing differentiated products that address the unmet needs of patients and clinicians, announced today that Dr. Robert Bilkovski, MD joined mPathix as our Chief Scientific Officer.
"Bob is a seasoned and experienced medical executive. His experience with both medical devices and pharmaceuticals is a perfect fit for mPathix's modality-agnostic business model. We look forward to Bob's effective leadership of our medical and clinical functions" said Demir Bingol, Chief Executive Officer of mPathix Health Inc.
About Dr. Bilkovski
Dr. Robert Bilkovski joined mPathix on July 12, 2021. He brings broad management experience to the CSO role, having served in leadership positions with Becton Dickinson, Abbott Labs, and GE Healthcare, overseeing medical affairs and clinical development in IVD, medical device and pharmaceuticals industries. Robert is also currently the President of RNB Ventures Consulting Inc., providing strategic consulting in the field of medical and clinical affairs for medical device and diagnostic companies. Dr. Bilkovski received his undergraduate degree in biochemistry with a focus in genetic engineering at McMaster University in Hamilton, Ontario, Canada. Robert completed his medical training at Rosalind Franklin University/The Chicago Medical School and subsequently pursued specialization in emergency medicine. Dr. Bilkovski earned his MBA at the University of Notre Dame as part of his transition from a clinical medicine to medical industry.
About Qualis Innovations Inc.
Qualis Innovations Inc. (Qualis) is a company that applies innovative technologies to improve the treatment, distribution, and access to care for patients suffering from diseases of the central nervous system. Qualis collaborates with other companies to bring new treatments to market using proprietary, best-in-class technologies.
About mPathix Health
mPathix Health, Inc.("mPathix"), is a wholly owned subsidiary of Qualis Innovations Inc. mPathix is focused on the development, production and distribution of multi-modal pain management and CNS related solutions. We are a clinical stage company, developing innovative pain management products using a modality-agnostic, virtual operating model. mPathix's lead product is the SOLACE electromagnetic induction device, which was originally cleared by FDA for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Contact:
mPathix Health Inc.
info@mpathixhealth.com
###
> Dow Jones Newswires
July 14, 2021 13:46 ET (17:46 GMT)
makinezmoney
3 년 전
$QLIS: CEO Demir Bingol
https://www.linkedin.com/in/demir-bingol-3a211612
Demir Bingol Contact Details
Location:
Greater Philadelphia Area
Work:
CEO @ Grünenthal USA, Inc
VP, Head of Business Development & Licensing, The Americas @ Grünenthal
Vice President, Commercial Marketing @ WellDoc, Inc
Education:
BSBA, Marketing @ Christopher Newport University
About:
VP, Head of Business Development & Licensing, The Americas @ From July 2013 to Present (2 years 4 months) Vice President, Commercial Marketing @ From June 2011 to June 2013 (2 years 1 month) Sr. Director, Oral Pain Solutions Group @ From 2006 to June 2011 (5 years) Sr. Marketing Director @ GI Strategic Marketing From 2004 to 2006 (2 years) Sr. Marketing Director @ CNS/Pain Marketing From 2002 to 2004 (2 years) Brand Director @ Cardiovascular and Respiratory Sales Respiratory Marketing From 1996 to 2002 (6 years) Area Director @ From September 1991 to January 1996 (4 years 5 months) Newport News, VA
MBA, Marketing @ Old Dominion University From 1992 to 1994 BSBA, Marketing @ Christopher Newport University From 1989 to 1991 Demir Bingol is skilled in: Marketing Strategy, Product Launch, Global Marketing, Sales Management, Segmentation
GO $QLIS
makinezmoney
3 년 전
$QLIS: mPathix Health inc...... Share Exchange Agreeement
https://www.globenewswire.com/news-release/2021/07/01/2256717/0/en/Qualis-Innovations-Inc-Completes-Share-Exchange-Agreement-with-mPathix-Health-Inc-formerly-EMF-Medical-Devices-Inc.html
Now 3.65
GO $QLIS
**********************************************
Qualis Innovations Inc. Completes Share Exchange Agreement with mPathix Health Inc. (formerly EMF Medical Devices, Inc.)
July 01, 2021 11:54 ET | Source: Qualis Innovations, Inc.
...
Chadds Ford, PA, July 01, 2021 (GLOBE NEWSWIRE) -- Qualis Innovation Inc. (“Qualis”) completed a share exchange agreement with mPathix Health Inc.(“mPathix”) through which mPathix will become a wholly owned subsidiary of Qualis. Qualis trades under the symbol “QLIS” on the OTC markets.
As a result of the share exchange, Qualis will install its new board of directors:
Demir Bingol, Chairman and CEO – Mr. Bingol served as Chairman and CEO of EMF Medical Devices since March 2021. Previously, Mr. Bingol headed business development and licensing for STADA Corp in the US. He was also vice president of business development and licensing for the Americas at Grünenthal USA and served as interim CEO from December 2017 through March 2019.
John Ballard, CFO and Board Member – Mr. Ballard served as the Chief Executive Officer for EMF Medical Devices from August 2019 through February 2021. Previously, Mr. Ballard has served as Chief Financial Officer of Worldwide Manufacturing USA, Inc., from September 2003 through May 2021.
Joseph Pergolizzi, MD, Board Member – Dr. Pergolizzi is an internationally recognized thought leader in anesthesiology, internal medicine, perioperative care, pain medicine, critical and palliative care, pharmacology, drug development, and regulatory affairs. He currently holds executive and board positions with several companies, including NEMA Research, Inc., Neumentum, Enalare Therapeutics Inc., and Native Cardio. Dr. Pergolizzi was a General Partner in the Life Science Equity Partners and has extensive executive board experience.
Jim Holt, Board Member – Mr. Holt is the current CEO of Life Care Medical Devices and is the President of CIM Securities. Mr. Holt has served on the Board of Directors for EMF Medical Devices since September 2019. Mr. Holt previously worked as a Wholesaler for Berger Mutual Funds and Oppenheimer Funds and is licensed Institutional MBS /CMO/CDO Trader.
Madding King, Board Member – Mr. King is a Founding Partner of Camp One Ventures, LLC, an early-stage venture capital fund with a focus on financial technology investments. Mr. King joined the EMF Medical Devices board in November 2019. Mr. King also co-founded and is the Chief Executive Officer of Brookline Group, LLC and is a Managing Director of Brookline Investments.
About Qualis Innovations Inc.
Qualis Innovations Inc. (Qualis) is a company that applies innovative technologies to improve the treatment, distribution, and access to care for patients suffering from diseases of the central nervous system. Qualis collaborates with other companies to bring new treatments to market using proprietary, best-in-class technologies.
About mPathix Health
mPathix Health, Inc.(“mPathix”), formerly EMF Medical Devices, Inc., is a wholly owned subsidiary of Qualis Innovations Inc. mPathix is focused on the development, production and distribution of multi-modal pain management and CNS related solutions. We are a clinical stage company, developing innovative pain management products using a modality agnostic, virtual operating model. mPathix’s lead product is the SOLACE electromagnetic induction device, which was originally cleared by FDA for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Contact:
mPathix Health Inc.
info@mpathixhealth.com
Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Renee
6 일 전
fink
3 년 전
Golden Cross
4 년 전
WHITTENHALLJR
4 년 전
